Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab with Sirolimus and Prednisone in Kidney Transplant Recipients with Advanced Cutaneous Cancers
NCT05896839Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2024
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in melanoma, Merkel cell carcinoma (MCC), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sponsored by National Cancer Institute. Started Jul 2024; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanomaMerkel cell carcinoma (MCC)basal cell carcinoma (BCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT05896839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896839.